88598-53-2Relevant academic research and scientific papers
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0438-0440, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0291-0293, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0271-0273, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0271-0173, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
A divergent synthesis of lipid A and its chemically stable unnatural analogues
Liu, Wen-Chi,Oikawa, Masato,Fukase, Koichi,Suda, Yasuo,Kusumoto, Shoichi
, p. 1377 - 1385 (2007/10/03)
Lipid A and its two chemically stable analogues, wherein the glycosidic phosphoryl groups in lipid A is replaced with 2-(phosphonooxy)ethyl or carboxymethyl groups, have been synthesized by an improved and divergent route via a common allyl glycoside intermediate in which the 4-hydroxy group was protected as a benzyl ether. The total yields were more than 20% for 11 or 12 steps starting from allyl 4,6-O-benzylidene-2-deoxy-2- (trichloroethoxycarbonylamino)-D-glucopyranoside. These synthetic chemically stable analogues induce interleukin-6 and tumor necrosis factor a in human peripheral whole blood cells with potencies comparable to those by natural- type synthetic lipid A. The Limulus activities of both analogues were found to be even stronger than the activity of the natural-type one.
Total Synthesis of Escherichia coli Lipid A, the Endotoxically Active Principle of Cell-Surface Lipopolysaccharide
Imoto, Masahiro,Yoshimura, Hiroyuki,Shimamoto, Tetsuo,Sakaguchi, Nobuki,Kusumoto, Shoichi,Shiba, Tetsuo
, p. 2205 - 2214 (2007/10/02)
Chemical synthesis are described of polyacylated β(1->6) glucosamine disaccharide 1,4'-bis(phosphate), which corresponds to the proposed structure of E. coli lipid A, and of its dephospho derivatives.The synthetic bisphosphate proved to be identical with
Chemical synthesis of 1-dephospho derivative of escherichia coli lipid A
Kusumoto,Yoshimura,Imoto,Shimamoto,Shiba
, p. 909 - 912 (2007/10/02)
1-Dephospho E. coli lipid A (3) was synthesized and shown to be identical with the corresponding derivative isolated from bacterial cells. This provides the unequivocal evidence supporting the structure of E. coli lipid A (2) recently proposed by us.
